Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dendritic Cell Vaccine in High Risk or Resected Metastatic Melanoma
NCT00019890Phase 2Completed
- Sponsor
- National Cancer Institute
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
01
Overview
Phase 2, randomised, open-label trial of MART-1-pulsed dendritic cells + gp100-pulsed dendritic cells in melanoma (2 arms), sponsored by National Cancer Institute. Primary endpoint: Immunologic activity of dendritic cells pulsed with MART-1 and gp100. Status: completed.
02
Drugs
MART-1-pulsed dendritic cells + gp100-pulsed dendritic cells
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00019890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00019890.